Comparison

AMGEN INC (AMGN) vs BRISTOL MYERS SQUIBB CO (BMY)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

AMGN

AMGEN INC

Drug Manufacturers—General

Revenue, FY25: $36.75B
Net income: $7.71B
Operating cash flow: $9.96B
Free cash flow: $8.1B
Net margin: 20.98%
Operating margin: 24.71%
Gross margin: 67.25%

BMY

BRISTOL MYERS SQUIBB CO

Drug Manufacturers—General

Revenue, FY25: $48.19B
Net income: $7.05B
Operating cash flow: $14.16B
Free cash flow: $12.85B
Net margin: 14.64%
Operating margin: -
Gross margin: 71.08%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	AMGN	BMY
Revenue growth, latest filed year	+9.95%	−0.22%
Piotroski F-score	7 of 9	8 of 9
P/E against its own history	about normal	22.05% below

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

AMGN

FDA approval
Reimbursement
Cybersecurity
Litigation
China
Tax

And 20 more.

BMY

Reimbursement
FDA approval
Litigation
Tax
Cybersecurity
Tariffs

And 19 more.

Tracked managers holding both

Joel Greenblatt Gotham Asset Management 0.04% · 0.12%
Dodge & Cox Dodge & Cox 0.00% · 0.00%

Updated Aug 5, 2026 · the newer of the two companies' filings